| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Centre d'étude du sommeil, Hôpital Sacré-Coeur et Faculté de Médicine, Université de Montréal, Québec, Canada.
Six patients with restless legs syndrome (RLS) and periodic movements during sleep (PMS) received placebo or L-dopa in a double-blind study. We recorded patients for 36 consecutive hours in the sleep laboratory during a baseline investigation and at the end of each treatment period. Daily evening questionnaires and a suggested immobilization test (SIT) performed at bedtime on each recording night documented the effect of L-dopa in RLS. A nocturnal EMG recording of the anterior tibialis muscles revealed the effect of L-dopa on PMS. L-Dopa proved effective in treating both RLS and PMS. Although not present in every patient, leg movements recorded during the SIT exhibited a clear periodicity. These observations support the hypothesis that RLS and PMS are two manifestations of the same central sensorimotor disorder.
Address correspondence and reprint requests to Dr. Montplaisir, Hôpital du Sacré-Coeur, Centre d'étude du sommeil, 5400 boul. Gouin Ouest, Montréal, Québec, H4J 1C5 Canada.
Supported by the Medical Research Council of Canada, the Fonds de la recherche en sante du Québec and the Fonds pour la formation de chercheurs et l'aide a la recherche du Québec.
Received March 8, 1988. Accepted for publication in final form June 1, 1988.
This article has been cited by other articles:
|
|
 |
|
  E. L. Unger, J. A. Wiesinger, L. Hao, and J. L. Beard Dopamine D2 Receptor Expression Is Altered by Changes in Cellular Iron Levels in PC12 Cells and Rat Brain Tissue J. Nutr., December 1, 2008; 138(12): 2487 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ryan and J. T. Slevin Restless Legs Syndrome Journal of Pharmacy Practice, December 1, 2007; 20(6): 430 - 448. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Ryan and J. T. Slevin Restless legs syndrome. Am. J. Health Syst. Pharm., September 1, 2006; 63(17): 1599 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Bogan, J. M. Fry, M. H. Schmidt, S. W. Carson, S. Y. Ritchie, and TREAT RLS US (Therapy with Ropinirole Efficacy And Ropinirole in the Treatment of Patients With Restless Legs Syndrome: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial Mayo Clin. Proc., January 1, 2006; 81(1): 17 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G G Tribl, T Sycha, N Kotzailias, J Zeitlhofer, and E Auff Apomorphine in idiopathic restless legs syndrome: an exploratory study J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 181 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Trenkwalder, H. -P. Hundemer, A. Lledo, J. Swieca, O. Polo, T. C. Wetter, L. Ferini-Strambi, H. de Groen, D. Quail, and U. Brandenburg Efficacy of pergolide in treatment of restless legs syndrome: The PEARLS Study Neurology, April 27, 2004; 62(8): 1391 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Trenkwalder, D Garcia-Borreguero, P Montagna, E Lainey, A W de Weerd, P Tidswell, G Saletu-Zyhlarz, W Telstad, and L Ferini-Strambi Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries J. Neurol. Neurosurg. Psychiatry, January 1, 2004; 75(1): 92 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Matheson and C. B. Saper REM sleep behavior disorder: A dopaminergic deficiency disorder? Neurology, November 25, 2003; 61(10): 1328 - 1329. [Full Text] [PDF]
|
|
|
|
|
|
D. Garcia-Borreguero, O. Larrosa, Y. de la Llave, K. Verger, X. Masramon, and G. Hernandez Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study Neurology, November 26, 2002; 59(10): 1573 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Comella Restless legs syndrome: Treatment with dopaminergic agents Neurology, February 1, 2002; 58(90001): S87 - 92. [Abstract] [Full Text]
|
|
|
|
|
|
N. Turjanski, A. J. Lees, and D. J. Brooks Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies Neurology, March 1, 1999; 52(5): 932 - 932. [Abstract] [Full Text]
|
|
|
|
|
|
T. C. Wetter, K. Stiasny, J. Winkelmann, A. Buhlinger, U. Brandenburg, T. Penzel, R. Medori, M. Rubin, W. H. Oertel, and C. Trenkwalder A randomized controlled study of pergolide in patients with restless legs syndrome Neurology, March 1, 1999; 52(5): 944 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Collado-Seidel, J. Kazenwadel, T. C. Wetter, R. Kohnen, J. Winkelmann, R. Selzer, W. H. Oertel, and C. Trenkwalder A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms Neurology, January 1, 1999; 52(2): 285 - 285. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. T. O'Keeffe Restless Legs Syndrome: A Review Arch Intern Med, February 12, 1996; 156(3): 243 - 248. [Abstract] [PDF]
|
|
|
|
 |
|
 Questions and Answers JAMA, June 12, 1991; 265(22): 3011 - 3014. [PDF]
|
|
|
|
 |
|
 A. S. Walters, D. Picchietti, W. Hening, and A. Lazzarini Variable Expressivity in Familial Restless Legs Syndrome Arch Neurol, November 1, 1990; 47(11): 1219 - 1220. [Abstract] [PDF]
|
|
|
|
|
|
C. von Scheele and V. Kempi Long-term Effect of Dopaminergic Drugs in Restless Legs: A 2-Year Follow-up Arch Neurol, November 1, 1990; 47(11): 1223 - 1224. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
